1Savoldo B,M.Huls H,Liu Z,et al.Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.Blood,2002;100:4059.
2Kasahara Y,Yachie A,Takei K,et al.Differential cellular targets of Epstein-Barr virus infection between actue EBV-associated hcmophagocytic lymphohistiocytosis and chronic active Epstein-Bart virus infection.Blood,2001;98:1882.
3Kimura H,Hoshino Y,Kanegane H,et al.Clinilcal and virologic characteristics of chronic active Epstein-Barr virus infection.Blood,2001;98:280.
4胡亚美 江载芳.诸福堂实用儿科学·第7版[M].北京:人民卫生出版社,2002.826.
5Imadome K,Shirakata M,Shimizu N,et al.CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation.Proc Natl Acad Sci U S A,2003;100:7836.
6Trempat P,Tabiasco J,Andre P,et al.Evidence for early infection of nonneoplastic natural killer cells by Epstein-Barr virus.Journal of virology,2002;76:11139.
7Katano H,Ali MA,Patera AC,et al.Chronic active Epstein-Bart virus infection associated with mutations in perforin that impair its maturation.Blood,2004;103:1244.
8Boer M,Mol M J,Bogman M J,et al.Chronic active Epstein-Barr virus infection in an adult with no detectable immune deficiency.Neth J Med,2003;61:376.
9Babel N,Hammer MH,Reinke P,et al.Adoptive transfer of Epstein-Barr virus-specific T-lymphocytes in chronic active Epstein-Barr infection.Dtsch Med Wochenschr,2003;128:548.
